Evidence map›Paper›PMID 42608543›Full record

ArticleJournal of human genetics2026

Clinical features of four unrelated Japanese patients with autosomal recessive spinocerebellar ataxia type 32.

Hiromi Fukuda, Hiroshi Doi, Shunsuke Ogata, Eriko Koshimizu, Kohei Hamanaka, Satoko Miyatake, Yuichi Higashiyama, Yosuke Kudo, Rumiko Kato, Takamasa Nukui and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hiromi Fukuda *Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiroshi Doi *Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. hdoi@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0001-5807-2523
Shunsuke OgataDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Eriko KoshimizuDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9947-3315
Kohei HamanakaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-5179-331X
Satoko MiyatakeDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-7587-5168
Yuichi HigashiyamaDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yosuke KudoDepartment of Neurology, Yokohama Municipal Citizens' Hospital, Yokohama, Japan.
Rumiko KatoDepartment of Pediatrics, National Hospital Organization Higashisaitama National Hospital, Saitama, Japan.
Takamasa NukuiDepartment of Neurology, Faculty of Medicine, Academic Research Division, University of Toyama, Toyama, Japan.
Kazuki YamadaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Shinichi ShiraiDepartment of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID http://orcid.org/0000-0001-9992-5254
Ichiro YabeDepartment of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID http://orcid.org/0000-0002-1734-7997
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-9846-6500
Fumiaki TanakaDepartment of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. ftanaka@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-9961-2693

Funding

Japan Agency for Medical Research and Development (AMED) JP22ek0109595Japan Agency for Medical Research and Development (AMED) JP23ek0109648Japan Agency for Medical Research and Development (AMED) JP25ek0109617Japan Agency for Medical Research and Development (AMED) JP25ek0109648Japan Agency for Medical Research and Development (AMED) JP25ek0109674Japan Agency for Medical Research and Development (AMED) JP25ek0109677Japan Agency for Medical Research and Development (AMED) JP25ek0109760
6 · The paper itself

Abstract

Peroxiredoxin 3 (PRDX3) encodes a mitochondrially localized antioxidant enzyme. Biallelic pathogenic variants in PRDX3 cause autosomal recessive spinocerebellar ataxia type 32 (SCAR32), a rare form of spinocerebellar ataxia. We report four unrelated Japanese patients with SCAR32 identified among 411 ataxia cases negative for repeat expansion disorders. Age at onset was 9-30 years, with a predominantly pure cerebellar phenotype; one patient had autoimmune comorbidities. MRI showed cerebellar atrophy and T2 hyperintensity in dentate nuclei in all patients, and three had cerebellar cortical T2 hyperintensity, a potentially representative feature of SCAR32. Genetic analysis identified one homozygous and three compound heterozygous PRDX3 nonsense variants: the previously reported p.Arg207* in all patients, p.Arg170* in two, and novel p.Gln50* in one. The relatively high p.Arg207* allele frequency in East Asians and the 0.97% prevalence in our undiagnosed ataxia cohort support SCAR32 as an important cause of early-onset autosomal recessive cerebellar ataxia in Japan.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.